{
    "title": "To require the National Institutes of Health to conduct research, and the Agency for Healthcare Research and Quality to conduct studies, on the comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals in federally funded health programs, and for other purposes.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Drug Comparative \nEffectiveness Act of 2003''.\n\nSEC. 2. NIH RESEARCH AND AHRQ STUDY ON EFFECTIVENESS OF CERTAIN \n              PRESCRIPTION DRUGS.\n\n    (a) In General.--\n            (1) Research by nih.--The Director of the National \n        Institutes of Health, in coordination with the Director of the \n        Agency for Healthcare Research and Quality, shall conduct \n        research, which may include clinical research, to develop valid \n        scientific evidence regarding the comparative effectiveness, \n        cost-effectiveness, and, where appropriate, comparative safety \n        of covered prescription drugs relative to other drugs and \n        treatments for the same disease or condition.\n            (2) Analysis by ahrq.--\n                    (A) In general.--The Director of the Agency for \n                Healthcare Research and Quality, taking into \n                consideration the research of the National Institutes \n                of Health under this section, shall use evidence-based \n                practice centers to conduct studies or other analyses \n                of the comparative effectiveness, cost-effectiveness, \n                and, where appropriate, comparative safety of covered \n                prescription drugs relative to other drugs and \n                treatments for the same disease or condition.\n                    (B) Safety.--In any analysis of comparative \n                effectiveness or cost-effectiveness under this \n                subparagraph, the Director of the Agency for Healthcare \n                Research and Quality shall include a discussion of \n                available information on relative safety.\n            (3) Standards.--The Director of the Agency for Healthcare \n        Research and Quality, in consultation with the Commissioner of \n        Food and Drugs, the Director of the National Institutes of \n        Health, and stakeholders, shall develop standards for the \n        design and conduct of cost-effectiveness studies under this \n        subsection.\n    (b) Covered Prescription Drugs.--For purposes of this section, the \nterm ``covered prescription drugs'' means prescription drugs that, as \ndetermined by the Director of the Agency for Healthcare Research and \nQuality in consultation with the Administrator of the Centers for \nMedicare & Medicaid Services, account for high levels of expenditures \nor use by individuals in federally funded health programs, including \nMedicare and Medicaid.\n    (c) Annual Report.--Each year the Director of the Agency for \nHealthcare Research and Quality shall prepare a report on the results \nof the research, studies, and analyses conducted by the National \nInstitutes of Health and the Agency for Healthcare Research and Quality \nunder this section and submit the report to the following:\n            (1) The Congress.\n            (2) The Secretary of Defense.\n            (3) The Secretary of Health and Human Services.\n            (4) The Secretary of Veterans Affairs.\n            (5) The Administrator of the Centers for Medicare & \n        Medicaid Services.\n            (6) The Director of the Indian Health Service.\n            (7) The Director of the National Institutes of Health.\n            (8) The Director of the Office of Personnel Management.\n    (d) Reports for Practitioners.--As soon as possible, but not later \nthan a year after the completion of any study pursuant to subsection \n(a)(2), the Director of the Agency for Healthcare Research and Quality \nshall--\n            (1) prepare a report on the results of such study for the \n        purpose of informing health care practitioners; and\n            (2) transmit the report to the Director of the National \n        Institutes of Health.\n    (e) NIH Internet Site.--The Director of the National Institutes of \nHealth shall publish on the Institutes' Internet site, and through \nother means that will facilitate access by practitioners, each report \nprepared under subsection (c) or (d) by the Director of the Agency for \nHealthcare Research and Quality.\n    (f) Evidence.--In carrying out this section, the Directors of the \nNational Institutes of Health and the Agency for Healthcare Research \nand Quality shall consider only methodologically sound studies, giving \npreference to studies for which the Directors have access to sufficient \nunderlying data and analysis to address any significant concerns about \nmethodology or the reliability of data.\n    (g) Authorizations of Appropriations.--\n            (1) NIH.--There are authorized to be appropriated to the \n        National Institutes of Health to carry out this section \n        $50,000,000 for fiscal year 2004, and such sums as may be \n        necessary for fiscal years thereafter.\n            (2) AHRQ.--There are authorized to be appropriated to the \n        Agency for Healthcare Research and Quality to carry out this \n        section $25,000,000 for fiscal year 2004, and such sums as may \n        be necessary for fiscal years thereafter."
}